Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL — Stella

Home/Relapse/Refractory B-cell Acute Lymphoblastic Leukemia/

View on ClinicalTrials.gov

Recruiting

Back to Relapse/Refractory B-cell Acute Lymphoblastic Leukemia trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Iran

Pediatric cell and gene therapy research center, Children medical center, Tehran, Tehran Province

Key details

Phase

Early testing / Safety & dosing

Sponsor

Kara Yakhteh Tajhiz Azma Company

Enrollment target

~5 participants

Started

May 2024

Primary completion

September 2026

Age range

2 Years – 18 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.